Drug
Levetiracetam
Levetiracetam: highest development phase Post-Market, developed by Sandoz, UCB, United Therapeutics. 9 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Sandoz, UCB, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Levetiracetam, Keppra NCT00223223 | Post-Market | Memory Loss Associated With Corticosteroid Use |
| levetiracetam NCT00245713 | Post-Market | Epilepsy, Partial |
| Levetiracetam NCT01498822 | Post-Market | Epilepsy |
| Levetiracetam (Keppra) NCT00630357 | Post-Market | Epilepsy |
| levetiracetam (Keppra) NCT00758277 | Phase 3 | Alcohol Dependence |
| levetiracetam NCT00291213 | Phase 3 | Tardive Dyskinesia |
| Levetiracetam NCT00615615 | Phase 3 | Epilepsy |
| levetiracetam NCT00627133 | Phase 2 | Seizure, Alcohol Related |
| Levetiracetam Tablets, 750 mg (Sandoz Inc.) NCT00946751 | Phase 1 | Seizure |
Latest
No recent events.
Follow Levetiracetam on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.